Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria
The oral complement factor B inhibitor iptacopan is an effective treatment option for paroxysmal nocturnal hemoglobinuria in patients with a suboptimal response to complement inhibitor C5 due to more effective control of extravascular C3-mediated hemolysis.
Authors
- Alexander Kulagin (ORCID: https://orcid.org/0000-0002-9589-4136)
- Irina K. Golubovskaya (ORCID: https://orcid.org/0000-0003-0469-7338)
- Olesya Klimova (ORCID: https://orcid.org/0000-0001-7238-729X)
- Мария Викторовна Марченко (ORCID: https://orcid.org/0009-0003-2740-4590)
- Yuriy N. Kuznetsov (ORCID: https://orcid.org/0000-0001-5738-7953)
Institutions
- First Pavlov State Medical University of St. Petersburg (RU)
Publication Details
- Journal
- Terapevticheskii arkhiv
- Published
- 2025-02-20
- DOI
- https://doi.org/10.26442/00403660.2025.01.203146
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00